The article discusses research regarding the use of bispecific broadly neutralizing antibodies (BibNAbs) in HIV-1. It references the study " Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1," by C. S. Pace and colleagues in the 2013 issue. The study found that the BibNAbs have the required antiviral potency and breadth for passive immunization.